Early diagnosis of upper digestive tract diseases using breath tests

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to improve the early diagnosis of upper digestive tract cancers, which are often detected late, leading to poor survival rates. It utilizes non-invasive breath testing technology that measures volatile organic compounds (VOCs) produced by metabolic processes in patients. By analyzing these biomarkers through mass spectrometry, the study seeks to identify patients with upper gastrointestinal cancers at an earlier stage than traditional diagnostic methods. The study includes patients undergoing endoscopy or surgical treatment for digestive tract diseases as part of their routine clinical care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Any patient who:

  * is ≥ 18 years old and below 90 years of age, AND:
  * is undergoing endoscopy as part of their routine clinical care, OR:
  * is undergoing surgical resection of orodigestive tract disease as part of their routine clinical care, OR:
  * is undergoing treatment of orodigestive tract disease as part of their routine clinical care

Exclusion Criteria:

* Any patient who:

  * Lacks capacity or is unable to provide informed consent.
  * Any patient below 18 years of age or over 90 years of age.

Where it's running

• Imperial College London
  London, United Kingdom Recruiting

Study contacts

• Study coordinator: Yan Mei Goh, MBChB, MRCS
• Email: y.goh@imperial.ac.uk
• Phone: 0207 594 3396

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia

  This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.

  Recruiting at 2 sites Phase 1 Rockefeller University · Minneapolis, Minnesota and 1 other locations · NCT07901959

• Two-photon microscopy on skin biopsies to help diagnose skin lesions

  This study tests whether images from two-photon fluorescence microscopy of dermatology biopsies can match the diagnosis determined by standard histology.

  Recruiting University of Rochester · Victor, New York · NCT07773688

• Targeted dual-imaging helper for head and neck cancer surgery

  This study tests whether using two imaging agents during surgery can help doctors see tumors and cancerous lymph nodes in adults with head and neck squamous cell carcinoma.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07741643

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• IDP-001 in advanced or metastatic solid tumors (including head and neck and skin cancers)

  A first- and second-phase study will test IDP-001 in people with advanced or metastatic solid tumors to see if it is safe and tolerable and to look for signs of activity.

  Recruiting at 6 sites Phase 1/2 InduPro, Inc. · Los Angeles, California and 5 other locations · NCT07602842

• Omitting postoperative radiation after HPV-related oropharyngeal cancer guided by ctHPVDNA monitoring

  This study tests whether some patients with HPV-related OPSCC can skip postoperative radiation after surgery if their tumors are low risk and ctHPVDNA looks negative.

  Recruiting Phase 2 Medical University of South Carolina · Charleston, South Carolina · NCT07513389

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.